What do systematic reviews say?

Risedronate 5 mg/day vs placebo

Risedronate 5 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).

• Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2022 · Cochrane Headline outcomes only
  RR 1 [0.94, 1.07]
  Studies not reported
  Moderate

Risedronate 5 mg/day vs placebo

It is very uncertain whether risedronate 5 mg/day changes serious adverse events compared with placebo (very low certainty).

• Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2022 · Cochrane Headline outcomes only
  RR 0.74 [0.42, 1.3]
  Studies not reported
  Very low

Febuxostat 80 mg/day vs placebo

Febuxostat 80 mg/day showed no clear difference in serious Adverse Events compared with placebo (moderate certainty).

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  RR 2.8 [0.72, 10.7]
  2 studies · 479 participants
  Moderate

Febuxostat 40 mg/day vs allopurinol

Febuxostat 40 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (high certainty).

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  RR 0.61 [0.35, 1.07]
  1 study · 1513 participants
  High

Febuxostat 80 mg/day vs allopurinol

Febuxostat 80 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (moderate certainty).

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  RR 0.91 [0.34, 2.4]
  3 studies · 1044 participants
  Moderate

Febuxostat 40 mg/day vs placebo

Febuxostat 40 mg/day probably leads to higher serious Adverse Events compared with placebo (moderate certainty).

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  RR 1 [0, 0]
  1 study · 75 participants
  Moderate

Febuxostat 120 mg/day vs placebo

Febuxostat 120 mg/day showed no clear difference in serious Adverse events compared with placebo (moderate certainty).

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  RR 2.7 [0.7, 10.2]
  2 studies · 479 participants
  Moderate

Febuxostat 120 mg/day vs allopurinol

Febuxostat 120 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (high certainty).

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  RR 1.2 [0.7, 1.93]
  3 studies · 1041 participants
  High

Intermittent/cyclic etidronate 400 mg/day vs placebo

• Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Intermittent/cyclic etidronate 400 mg/day vs placebo

Intermittent/cyclic etidronate 400 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).

• Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2024 · Cochrane Headline outcomes only
  RR 0.9 [0.52, 1.54]
  Studies not reported
  Moderate